Document Detail

Metabolic syndrome does not increase angiographic restenosis rates after drug-eluting stent implantation.
MedLine Citation:
PMID:  18442619     Owner:  NLM     Status:  MEDLINE    
Metabolic syndrome (MS) is associated with an increased risk of coronary heart disease, stroke, and cardiovascular mortality; but its effect on patients undergoing cardiac revascularization is still unclear. Robust evidence demonstrates that diabetes mellitus and insulin resistance are among the main risk factors for restenosis in patients requiring percutaneous myocardial revascularization. The recent advent of drug-eluting stents (DESs) has significantly reduced the incidence of restenosis compared with bare-metal stents, both in nondiabetic and in diabetic patients. The aim of the study was to evaluate the effect of MS on the risk of binary restenosis in DES implant recipients. One hundred eighty-nine recipients of successful DES implants performed between January and March 2005 for stable coronary artery disease underwent 1-year clinical and angiographic follow-up. Body mass index (BMI), blood pressure, fasting blood glucose, and lipid profile were determined. Metabolic syndrome was defined according to the National Cholesterol Education Program Adult Treatment Panel III criteria, with the waist criterion being substituted by a BMI>or=28.8 kg/m2. Metabolic and anthropometric information for MS diagnosis was available for 148 of 189 patients; 87 of 148 patients (58%) had MS. Patients with MS had higher BMI (28.4+/-3.8 vs 26+/-2.7 kg/m2, P<.0001), systolic blood pressure (133+/-14 vs 124+/-14 mm Hg, P=.0004), and fasting glucose (113+/-37 vs 92+/-17 mg/dL, P<.0001). They also had higher serum triglycerides (154+/-94 vs 113+/-43, P=.0018) and lower high-density lipoprotein cholesterol levels (39+/-9 vs 46+/-10, P<.0001). Rates of restenosis (10.5% vs 8.1%, P=not significant [NS]), target vessel revascularization (10.5% vs 11.3%, P=NS), and major adverse cardiac events (11.6% vs 14.5%, P=NS) were not significantly different in patients with MS compared with those without MS, nor was any association found between increased end point risk and presence of MS. When patients were subdivided into 6 subgroups by the presence of 0, 1, 2, 3, 4, or 5 of the MS components, restenosis rates were not significantly different among subgroups. In conclusion, MS is not associated with higher rates of restenosis, target vessel revascularization, or major adverse cardiac events; and no additional MS feature was associated with an increased risk.
Paola Canibus; Emanuela Faloia; Tommaso Piva; Andi Muçai; Massimiliano Serenelli; Gian Piero Perna; Marco Boscaro; Roberto Piva
Related Documents :
2299089 - Restenosis after coronary angioplasty: new standards for clinical studies.
21180399 - Promises and pitfalls in cell replacement therapy for heart failure.
21487029 - Heterogeneous cardiac proteasomes: mandated by diverse substrates?
18000749 - A meta-analysis of stem cell mobilization by granulocyte colony-stimulating factor in t...
17354579 - Possible predictors of target lesion revascularization after drug-eluting stent implant...
15209579 - Low rates of angiographic and clinical restenosis with the new flexible medstent for th...
18375399 - Reperfusion after primary angioplasty for st-elevation myocardial infarction: predictor...
24344659 - Diagnosis of myocardial infarction in women: are we doing our best?
12467849 - Carotid artery intima-media thickness and plaque score for the risk assessment of strok...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Metabolism: clinical and experimental     Volume:  57     ISSN:  0026-0495     ISO Abbreviation:  Metab. Clin. Exp.     Publication Date:  2008 May 
Date Detail:
Created Date:  2008-04-29     Completed Date:  2008-06-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0375267     Medline TA:  Metabolism     Country:  United States    
Other Details:
Languages:  eng     Pagination:  593-7     Citation Subset:  IM    
Division of Endocrinology, Polytechnic University of Marche, and Department of Cardiovascular Diseases, G.M. Lancisi Hospital, Ancona, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angioplasty, Transluminal, Percutaneous Coronary*
Coronary Angiography
Coronary Restenosis / epidemiology*,  etiology
Drug-Eluting Stents*
Metabolic Syndrome X / complications*
Middle Aged

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Coronary connector devices: analysis of 1,469 anastomoses in 1,216 patients.
Next Document:  Baseline inflammatory markers do not modulate the lipid response to weight loss.